endpts.com·Jun 8, 2026
Cavalry Biosciences is seeking $75 million in a Series B funding round to advance the development of its drugs targeting eye and muscle disorders. This marks the company's first major funding effort since emerging from the incubator Jupiter Bioventures.
Cavalry Biosciences' pursuit of a $75 million Series B round to test drugs for eye and muscle disorders is a significant investment signal in the biotech field. This indicates a growing interest and potential in targeting niche therapeutic areas, which could lead to innovative treatments and a valuable opportunity for stakeholders focusing on precision medicine and biotech investments.